Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) added 1.13% by the end of trading session at $10.76. For the current quarter, the 7 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$1.07/share, which would compare with -$1.5 in the year-ago quarter. The net percentage change is 74.96% over the last 12 months. The trading range in the same period had a highest hit of $16.5 while lowest level was $4.03. At the moment the price is -16.7% below its 50-day moving average and 8.41% above its 200-day moving average.

PTC Therapeutics, Inc. (NASDAQ:PTCT) on March 13, 2017 announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company’s business and outlook on Thursday, March 16, 2017 at 8:30 a.m. (ET) before the opening of the market. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.

Geron Corporation (NASDAQ:GERN) last exchanged hands at a price $2.13/share, registering a gain of 0.95%. Among 3 Wall Street analysts tracked by Thomson/First Call, the average PT for GERN is $4.17 but some of them are predicting the price to move at the $5 level. If the most optimistic analysts are correct, the expected total return from the current price would be 134.74. The number of shares traded in most recent trading day was 0.93M shares which averages 1.41M shares a day. Its previous fifty two week high was $3.35 and moved down -23.93% over the same time frame, currently having a market cap around $338.99 million. Shares have risen 1.91% over the trailing six months. At the moment, the stock trades 0.3% above its 50-day moving average and -9.61% below its 200-day moving average.

Geron Corporation (NASDAQ:GERN) on March 2, 2017 announced an abstract submitted by Janssen Research & Development, LLC describing non-clinical data on imetelstat has been accepted for presentation as a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, D.C. from April 1-5, 2017.

In accordance with AACR policies, abstracts submitted to the AACR Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR Annual Meeting.